E
REPL icon

Ergoteles’s Replimune Group REPL Stock Holding History

Ergoteles’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,170
Closed -$422K – 662
2023
Q2 		$422K Buy
+18,170
New +$355K 0.02% 681
2022
Q1 		– Sell
-13,927
Closed -$377K – 1573
2021
Q4 		$377K Buy
+13,927
New +$417K 0.01% 767

Other funds holding REPL

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Ergoteles's REPL Position: Q3 2023 in Review

Ergoteles sold out of Replimune Group (REPL) in Q3 2023, closing a stake of 18,170 shares — an estimated $422K sold.

Ergoteles first reported a position in REPL in Q4 2021 and held it in 2 quarters. The position peaked at $422K in Q2 2023. 127 funds tracked by Wall St. Rank hold REPL as of Q3 2023.

  • Ergoteles reported no remaining Replimune Group position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 18,170 Replimune Group shares in Q3 2023, an estimated $422K.
  • Ergoteles first reported a position in Replimune Group in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Replimune Group position peaked at $422K in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Replimune Group as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.